Welcome
Support Centre
13 October 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Control of Rheumatoid Arthritis (RA) by oral tolerance
ISRCTN ISRCTN98945627
ClinicalTrials.gov identifier
Public title Control of Rheumatoid Arthritis (RA) by oral tolerance
Scientific title
Acronym N/A
Serial number at source S0523
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Rheumatoid arthritis
Participants - inclusion criteria 1. RA patients aged over 18 and fulfilling the 1987 American College of Rheumatology (ACR) criteria for the diagnosis of RA were entered into the study after giving their written informed consent
2. Patients must have had the disease at least two years and have failed at least one Slow Acting Anti-Rheumatic Drug (SAARD)
3. All the patients had to have active arthritis defined by the presence of three out of four clinical criteria: three or more swollen joints, six or more tender joints, early morning stiffness over 45 minutes and Erythrocyte Sedimentation Rate (ESR) over 28 mm/h. Oral steroid treatment was permitted if the dose was more than 10 mg/day
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/1998
Anticipated end date 01/01/2000
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Patients were randomly assigned to receive either 0.05 mg, 0.5 mg or 5 mg daily of bovine type II collagen (CII) or placebo for six months
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Arthritis Research Campaign (UK)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11592359
Contact name Dr  Ernest  Choy
  Address Academic Department of Rheumatology
GKT School of Medicines
King's College Hospital (Dulwich)
East Dulwich Grove
  City/town London
  Zip/Postcode SE22 8PT
  Country United Kingdom
  Tel +44 (0)20 7346 6446
  Fax +44 (0)20 7346 6475
  Email ernest.choy@kcl.ac.uk
Sponsor Arthritis Research Campaign (ARC) (UK)
  Address Copeman House
St Mary's Court
St Mary's Gate
Chesterfield
  City/town Derbyshire
  Zip/Postcode S41 7TD
  Country United Kingdom
  Email info@arc.org.uk
  Sponsor website: http://www.arc.org.uk
Date applied 18/07/2002
Last edited 04/10/2007
Date ISRCTN assigned 18/07/2002
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central